Alvotech and Teva announced FDA acceptance of the Biologics License Application (BLA) for AVT05, a proposed biosimilar ...

Key Insights Alvotech's significant private equity firms ownership suggests that the key decisions are influenced ...

In trading on Wednesday, shares of Alvotech (Symbol: ALVO) crossed below their 200 day moving average of $12.51, changing hands as low as $12.43 per share. Alvotech shares are currently trading ...

The U.S. Food and Drug Administration (FDA) has accepted for review Biologics License Applications (BLA) for AVT05, ...

Alvotech (ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced that the FDA has ...

Alvotech, a biotech company focused on developing biosimilar medicines, announced its inclusion in the Nasdaq Biotechnology Index (NBI) as part of the index's annual reconstitution, effective ...

Has Alvotech (ALVO) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.

Alvotech (ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced that the U.S. FDA has ...

The FDA accepted applications for a golimumab biosimilar, while Samsung Biologics reported record sales, and a Japanese ...

Alvotech (ALVO) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's ...

The FDA has accepted Alvotech (ALVO) and Teva's (TEVA) applications for AVT05, their proposed biosimilar to J&J's ...